Literature DB >> 18535159

MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.

Mark Eilers1, Upal Roy, Debasis Mondal.   

Abstract

The constituents of highly active anti-retroviral therapy (HAART) include HIV-1 protease inhibitors (HPIs) and nucleoside reverse transcriptase inhibitors (NRTIs). Endothelial cell (EC) barriers, especially the blood-brain-barrier (BBB) suppresses the entry of HAART drugs to subendothelial HIV-1 reservoirs. The ATP binding cassette (ABC) transporter family members, multidrug resistant-1 (MDR-1) and multidrug resistance-associated proteins (MRPs) can efflux both HPIs and NRTIs from intracellular compartments. Using brain derived ECs from non-human sources, previous studies suggested a dominant role for MDR-1 in HAART efflux from the BBB. However, due to species variations in ABC-transporter expression, drug-efflux functions using human brain ECs need to be investigated. Furthermore, roles of ABC-transporters in drug-efflux from systemic EC barriers need to be studied. We monitored the expression of ABC-transporters in primary human ECs obtained from brain (HBMVECs), aorta (HAECs), pulmonary-artery (HPAECs), dermal-microvessel (HDMVECs) and umbilical vein (HUVECs). Gene expression for MDR-1 and MRPs (MRP-1 to MRP-5) were analyzed by reverse transcriptase polymerase chain reaction (RT-PCR). Drug efflux functions were determined by calcein retention assays. Intracellular accumulation of both 3H-saquinavir (an HPI) and 3H-zidovudine (an NRTI) were also monitored in HAECs and HBMVECs. Both assays were carried out in presence of verapamil (20-60 microM) or MK-571 (12.5-50 microM) inhibitors of MDR-1 and MRPs, respectively in presence of verapamil or MK-571. The HBMVECs expressed higher levels of MRPs than MDR-1 and only MK-571 significantly (P<0.01) suppressed calcein efflux from these cells. However, both HAECs and HPAECs showed MDR-1 and MRP expression and calcein efflux was inhibited by both verapamil and MK-571. Both inhibitors suppressed 3H-saqubinavir efflux from HAECs, but only MK-571 suppressed saquinavir efflux from HBMVECs. In both ECs, 3H-zidovudine efflux was only suppressed by MK-571. Thus, primary human ECs, especially brain derived ECs, predominantly express MRPs and their specific inhibition may enhance HAART efficacy in subendothelial HIV-1 reservoirs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18535159      PMCID: PMC2575034          DOI: 10.3181/0802-RM-59

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  66 in total

Review 1.  The role of cytochrome P450 in antiretroviral drug interactions.

Authors:  Andrew Walubo
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-08       Impact factor: 4.481

2.  Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.

Authors:  Miki Katoh; Naoto Suzuyama; Toshiyuki Takeuchi; Sumie Yoshitomi; Satoru Asahi; Tsuyoshi Yokoi
Journal:  J Pharm Sci       Date:  2006-12       Impact factor: 3.534

Review 3.  Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.

Authors:  Stefano Aquaro; Valentina Svicher; Dominique Schols; Michela Pollicita; Andrea Antinori; Jan Balzarini; Carlo Federico Perno
Journal:  J Leukoc Biol       Date:  2006-08-24       Impact factor: 4.962

4.  Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line.

Authors:  Jun Hua; David G Mutch; Thomas J Herzog
Journal:  Gynecol Oncol       Date:  2005-07       Impact factor: 5.482

5.  Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice.

Authors:  Jonathan M Maher; Angela L Slitt; Nathan J Cherrington; Xingguo Cheng; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2005-03-31       Impact factor: 3.922

6.  P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice.

Authors:  Seonghee Park; Patrick J Sinko
Journal:  J Pharmacol Exp Ther       Date:  2004-11-04       Impact factor: 4.030

Review 7.  Multidrug resistance-associated proteins: expression and function in the central nervous system.

Authors:  Shannon Dallas; David S Miller; Reina Bendayan
Journal:  Pharmacol Rev       Date:  2006-06       Impact factor: 25.468

8.  Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein.

Authors:  Jeffrey G Sarver; Wieslaw A Klis; James P Byers; Paul W Erhardt
Journal:  J Biomol Screen       Date:  2002-02

9.  Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.

Authors:  Monica Biscardi; Elisabetta Teodori; Roberto Caporale; Roberta Budriesi; Francesca Balestri; Barbara Scappini; Sabrina Gavazzi; Alberto Grossi
Journal:  Leuk Res       Date:  2005-08-02       Impact factor: 3.156

Review 10.  Anti-HIV drug distribution to the central nervous system.

Authors:  S A Thomas
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more
  31 in total

Review 1.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

2.  Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Authors:  Eric H Decloedt; Bernd Rosenkranz; Gary Maartens; John Joska
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

Review 3.  Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Authors:  Michelle A Erickson; William A Banks
Journal:  Pharmacol Rev       Date:  2018-04       Impact factor: 25.468

Review 4.  Transepithelial transport across the blood-testis barrier.

Authors:  Siennah R Miller; Nathan J Cherrington
Journal:  Reproduction       Date:  2018-12       Impact factor: 3.906

5.  Amphiphilic cationic nanogels as brain-targeted carriers for activated nucleoside reverse transcriptase inhibitors.

Authors:  G Warren; E Makarov; Y Lu; T Senanayake; K Rivera; S Gorantla; L Y Poluektova; S V Vinogradov
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-06       Impact factor: 4.147

6.  The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Authors:  Omar Janneh; Andrew Owen; Patrick G Bray; David J Back; Munir Pirmohamed
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

7.  Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.

Authors:  Upal Roy; Geetika Chakravarty; Kerstin Honer Zu Bentrup; Debasis Mondal
Journal:  Biol Pharm Bull       Date:  2009-12       Impact factor: 2.233

8.  PharmGKB summary: zidovudine pathway.

Authors:  Yogita Ghodke; Peter L Anderson; Katrin Sangkuhl; Jatinder Lamba; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-12       Impact factor: 2.089

9.  Lipopolysaccharide increases the expression of multidrug resistance-associated protein 1 (MRP1) in RAW 264.7 macrophages.

Authors:  Peter S Silverstein; Kenneth L Audus; Nilofer Qureshi; Anil Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-06       Impact factor: 4.147

Review 10.  Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Authors:  Minjee Kim; Sani H Kizilbash; Janice K Laramy; Gautham Gampa; Karen E Parrish; Jann N Sarkaria; William F Elmquist
Journal:  Pharm Res       Date:  2018-07-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.